# FDA Inspection 1081613 - Biomat USA, Inc - February 22, 2019

Source: https://www.keypedia.com/records/fda_inspections/biomat-usa-inc/493bdd27-3546-4515-b94e-33c8487b5608
Source feed: FDA_Inspections

> FDA Inspection 1081613 for Biomat USA, Inc on February 22, 2019. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1081613
- Company Name: Biomat USA, Inc
- Inspection Date: 2019-02-22
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 968454 - 2016-05-05](https://www.keypedia.com/records/fda_inspections/biomat-usa-inc/d4e03f69-74d9-4aab-a800-2fc57f2cad65)
- [FDA Inspection 834748 - 2013-05-30](https://www.keypedia.com/records/fda_inspections/biomat-usa-inc/6ef921c1-7a98-483f-960b-5cf464e1f51e)
- [FDA Inspection 709252 - 2011-02-07](https://www.keypedia.com/records/fda_inspections/biomat-usa-inc/c9700378-cb5e-41bd-bcb6-9e36681ec623)

Company: https://www.keypedia.com/companies/biomat-usa-inc/29cb5f4f-ed84-4bd3-a5f2-e640a86ab7d2

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d